Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Abstract EN

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors.

We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients.

Ten healthy controls were recruited.

Serum Lumican and Endocan levels were analyzed using ELISA kits.

O&O patients had lower levels of Endocan compared to healthy controls (p<0.001).

There were no differences between serum Endocan levels in O&O patients with NAFLD and those without (p=0.53).

Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH (p=0.026).

Patients with metabolic syndrome had lower levels of Endocan (p=0.003).

There were no significant differences between serum Lumican levels in O&O children compared to healthy controls.

Lumican levels were higher in patients with hypertension (p=0.04).

In O&O patients, Lumican levels were negatively correlated with Endocan levels (r=−0.37, p=0.002).

Endocan seems a promising biomarker for the evaluation of pediatric NASH.

Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure.

Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.